BioCentury | Oct 11, 2004
Clinical News

MS-325 regulatory update

...The company said the extension notification did not include a request for any new data. Epix Medical Inc....
BioCentury | Aug 9, 2004
Clinical News

EP-2104R: Phase I started

...EPIX began a U.S. Phase I trial in an undisclosed number of patients. Epix Medical Inc. (EPIX), Cambridge...
BioCentury | Aug 2, 2004
Company News

Epix Medical board of directors update

Epix Medical Inc. (EPIX), Cambridge, Mass. Business: Diagnostic Appointed: Gregory Phelps, formerly CEO and a director of Ardais Corp. WIR Staff Diagnostic...
BioCentury | Jul 19, 2004
Clinical News

MS-325: Phase IIa started

...trial. The companies have submitted an NDA and an MAA for MS-325 for vascular imaging. Epix Medical Inc....
BioCentury | Jul 19, 2004
Company News

Epix Medical management update

Epix Medical Inc. (EPIX), Cambridge, Mass. Business: Diagnostic Hired: Andrew Uprichard as president and COO, formerly COO of ArQule Inc. WIR Staff...
BioCentury | Jun 14, 2004
Clinical News

MS-325 regulatory update

...for filing the MS-325 NDA, which has a mid-October PDUFA date (see BioCentury, Feb. 23). Epix Medical Inc....
BioCentury | Mar 15, 2004
Company News

Epix Medical management update

Epix Medical Inc. (EPIX), Cambridge, Mass. Business: Diagnostic Promoted: Thomas McMurry to VP of research from executive director of discovery and IP WIR Staff Diagnostic...
BioCentury | Feb 23, 2004
Clinical News

MS-325 regulatory update

...MRA ) contrast agent for vascular imaging. The NDA has a mid-October PDUFA date. Epix Medical Inc....
BioCentury | Dec 22, 2003
Clinical News

MS-325 regulatory update

...for MS-325 injectable gadolinium magnetic resonance angiography ( MRA ) contrast agent for vascular imaging. Epix Medical Inc....
BioCentury | Dec 8, 2003
Clinical News

MS-325: Phase II results; Phase III

...mmol/kg and higher, MS-325 gave a 20% increase in accuracy. Results were published in Radiology. Epix Medical Inc....
Items per page:
1 - 10 of 83
BioCentury | Oct 11, 2004
Clinical News

MS-325 regulatory update

...The company said the extension notification did not include a request for any new data. Epix Medical Inc....
BioCentury | Aug 9, 2004
Clinical News

EP-2104R: Phase I started

...EPIX began a U.S. Phase I trial in an undisclosed number of patients. Epix Medical Inc. (EPIX), Cambridge...
BioCentury | Aug 2, 2004
Company News

Epix Medical board of directors update

Epix Medical Inc. (EPIX), Cambridge, Mass. Business: Diagnostic Appointed: Gregory Phelps, formerly CEO and a director of Ardais Corp. WIR Staff Diagnostic...
BioCentury | Jul 19, 2004
Clinical News

MS-325: Phase IIa started

...trial. The companies have submitted an NDA and an MAA for MS-325 for vascular imaging. Epix Medical Inc....
BioCentury | Jul 19, 2004
Company News

Epix Medical management update

Epix Medical Inc. (EPIX), Cambridge, Mass. Business: Diagnostic Hired: Andrew Uprichard as president and COO, formerly COO of ArQule Inc. WIR Staff...
BioCentury | Jun 14, 2004
Clinical News

MS-325 regulatory update

...for filing the MS-325 NDA, which has a mid-October PDUFA date (see BioCentury, Feb. 23). Epix Medical Inc....
BioCentury | Mar 15, 2004
Company News

Epix Medical management update

Epix Medical Inc. (EPIX), Cambridge, Mass. Business: Diagnostic Promoted: Thomas McMurry to VP of research from executive director of discovery and IP WIR Staff Diagnostic...
BioCentury | Feb 23, 2004
Clinical News

MS-325 regulatory update

...MRA ) contrast agent for vascular imaging. The NDA has a mid-October PDUFA date. Epix Medical Inc....
BioCentury | Dec 22, 2003
Clinical News

MS-325 regulatory update

...for MS-325 injectable gadolinium magnetic resonance angiography ( MRA ) contrast agent for vascular imaging. Epix Medical Inc....
BioCentury | Dec 8, 2003
Clinical News

MS-325: Phase II results; Phase III

...mmol/kg and higher, MS-325 gave a 20% increase in accuracy. Results were published in Radiology. Epix Medical Inc....
Items per page:
1 - 10 of 83